Akebia Therapeutics vs Rockwell Medical
AKBA and RMTI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AKBA and RMTI compare
Akebia Therapeutics is the larger company, worth 4.2 times as much as Rockwell Medical ($111M against $26.6M).
Akebia Therapeutics grew revenue faster over the last twelve months (7.5% versus −21.1% for Rockwell Medical).
Rockwell Medical keeps more of each dollar of sales as profit, with a net margin of −7.3% compared with −13.5% at Akebia Therapeutics.
Rockwell Medical scores higher on the StockData Score (11 against 6 for Akebia Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AKBA | RMTI |
|---|---|---|
| Size and price | ||
| Market cap | $111M | $26.6M |
| Share price | $0.400 | $6.61 |
| Change, 1 year | −76.0% | −28.1% |
| Change, 5 years | −85.0% | −86.3% |
| Beta (5Y) | 1.20 | 0.01 |
| Employees | 194 | 157 |
| StockData Score | ||
| Total score | 6 | 11 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 2 (better) | 1 |
| Performance score | 2 | 3 (better) |
| Health score | 2 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.5× | 0.4× (better) |
| P/B | 4.4× | 0.8× (better) |
| P/FCF | 2.8× (better) | 17.3× |
| FCF yield | 36.3% (better) | 5.8% |
| Fair value | – | $32.27 |
| Margin of safety | – | 79.5% |
| Growth | ||
| Revenue growth (TTM) | 7.5% (better) | −21.1% |
| Revenue growth, 5Y average | −4.3% | 2.2% (better) |
| Profitability | ||
| Gross margin | 79.6% (better) | 17.7% |
| Operating margin | −6.9% | −6.5% (better) |
| Net margin | −13.5% | −7.3% (better) |
| FCF margin | 18.4% (better) | 2.2% |
| Return on equity | −109% | −15.5% (better) |
| Return on invested capital | – | −17.9% |
| Financial health | ||
| Debt / equity | 1.98 | 0.26 (better) |
| Interest coverage | – | −4.0× |
| Current ratio | 1.43 | 3.25 (better) |
| Altman Z-score | −5.89 (better) | −7.81 |
| Piotroski F-score | 7 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 39.7% | 0.05% |
| Held by insiders | 2.9% | 100% |
| Insider net buying, 12 months | −$876K | −$11.6K (better) |
| Short interest, % of float | 10.1% | – |
Go deeper
- AKBA stock overview
- AKBA income statement
- AKBA valuation and score
- RMTI stock overview
- RMTI income statement
- RMTI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.